Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus R-CHOP versus placebo plus R-CHOP in previously untreated CD20-positive diffuse large B-cell lymphoma
2006-005520-16Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Bevacizumab + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival. Started Mar 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2006-005520-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005520-16.